Plymouth Meeting-based Harmony Biosciences Holdings has appointed Peter Anastasiou, chief executive officer of a development stage company Capsida, to the company’s board of directors.

Prior to running Capsida, Anastasiou held various leadership positions at Lundbeck, including President of North America and U.S. Chief Commercial Officer.

As part of his roles, he oversaw U.S. and Canadian business operations and directed the commercial operations of Lundbeck’s neurology and psychiatry franchises.

“I am energized to join Harmony’s board of directors at this critical stage of growth for the company,” said Anastasiou.

He added that he has dedicated his entire professional career to the mission of bringing new treatment options to individuals living with unmet medical needs.

This makes Harmony, a pharmaceutical company that focuses on developing and commercializing innovative therapies for patients with rare neurological diseases, the perfect fit for him.

“I look forward to supporting this dedicated management team and working with the other visionary leaders on the board of directors as we explore opportunities to bring new treatments to people living with rare neurological diseases,” he said.

Anastasiou held management roles in several other companies, including Neuronetics, Bristol-Myers Squibb Company, and Eli Lilly.

Read more about Peter Anastasiou and his new role at Harmony Biosciences Holdings.

________________